Eternity in Medical Information -- Medisurf
Search | Web Directory, News, Variable useful Information, PubMed In Medine, All
Category Select :
Items 61 ~ 80 of 25905, Page 4 of 1296
61. ACS Report: More Effort Needed to Reduce Cancer Risk in the US
avoiding tobacco, staying at a healthy weight, eating a healthy diet, limiting alcohol, getting enough physical activity, and getting recommended screenings and vaccinations
04/03/2019 American Cancer Society
62. FDA takes new steps to increase access to adverse event report data for medical products used in animals
04/03/2019 U.S. FOOD & DRUG ADMINISTRATION
63. Statement on steps toward a new, tailored review framework for artificial intelligence-based medical devices
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
64. Bariatric Embolization Shows Promise in Treatment of Obesity
Bariatric embolization, a new, minimally invasive treatment for obesity produces weight loss and reduces appetite for up to one year, according to a new study published in the journal Radiology.
04/02/2019 Radiological Society of North America
65. Older Women Benefit Significantly When Screened with 3-D Mammography
Mammography remains an effective method for breast cancer screening in women ages 65 and older, with the addition of a 3-D technique called tomosynthesis improving screening performances even more, according to a study published in the journal Radiology.
04/02/2019 Radiological Society of North America
66. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s continued efforts to bring competition to the insulin market to lower prices and expand access
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
67. FDA takes new enforcement actions as part of the agency’s ongoing effort to combat the illegal online sales of opioids
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
68. Statement on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
69. Merck Completes Tender Offer to Acquire Immune Design
04/02/2019 MERCK
70. USDA, EPA, and FDA Recognize April as Winning on Reducing Food Waste Month
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
71. Merck to Hold First-Quarter 2019 Sales and Earnings Conference Call on April 30
04/02/2019 MERCK
72. Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1
Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas / Selumetinib Is a MEK 1/2 Inhibitor Being Co-Developed by AstraZeneca and Merck
04/01/2019 MERCK
73. Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals
04/01/2019 MERCK
74. Statement on new efforts to advance treatment strategies for helping youth addicted to nicotine as a result of the epidemic rise in teen use of e-cigarettes
04/01/2019 U.S. FOOD & DRUG ADMINISTRATION
75. FDA warns homeopathic firms for putting patients at risk with significant violations of manufacturing quality standards
04/01/2019 U.S. FOOD & DRUG ADMINISTRATION
76. Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China
04/01/2019 MERCK
77. Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019
First Presentation of Overall Survival Data from Post-Hoc Analysis of KEYNOTE-189 in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Who Have Liver or Brain Metastases / Pooled Data in Patients with Previously Treated Advanced Small Cell Lung Cancer in AACR 2019 Plenary Session and Press Conference
04/01/2019 MERCK
78. FDA approves new oral treatment for multiple sclerosis
03/29/2019 U.S. FOOD & DRUG ADMINISTRATION
79. Statement by FDA Commissioner Scott Gottlieb, M.D., Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access ?Looking Forward
03/29/2019 U.S. FOOD & DRUG ADMINISTRATION
80. FDA approves treatment for patients with a type of inflammatory arthritis
03/28/2019 U.S. FOOD & DRUG ADMINISTRATION
   
1 2 3 4 5 6 7 8 9 10
 
경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱